Core Insights - In 2024, Hubei's health industry has historically surpassed the trillion yuan scale, becoming a significant part of the national biopharmaceutical landscape [1] - Hubei is reshaping its industrial chain through innovation, setting a benchmark for the central region and demonstrating local wisdom in the Healthy China strategy [1] Industry Overview - The biopharmaceutical industry is a strategic emerging industry crucial for national security and public welfare [2] - Hubei's biopharmaceutical manufacturing revenue reached 123.5 billion yuan in 2024, a 3.5% increase year-on-year, ranking 8th nationally [2] - The province aims to double its biopharmaceutical revenue to 250 billion yuan by 2027, with plans to develop 150 flagship products and establish 2-3 CXO platforms with over 2 billion yuan in revenue [2] Growth Drivers - Hubei's health industry revenue grew from 881 billion yuan in 2023 to over 1 trillion yuan in 2024, driven by the rapid development of key enterprises [3] - The province has 644 regulated biopharmaceutical companies, generating a total profit of 14.84 billion yuan, with 24 listed companies, ranking 7th nationally [3] - Hubei has established 6 national manufacturing champions and 34 national specialized "little giant" enterprises, contributing to stable growth in the pharmaceutical industry [3] Technological Advancements - Hubei is focusing on breakthrough technologies and developing innovative drugs, particularly in AI healthcare and life sciences [4] - The province's chemical raw materials profit margin increased by 33.2% in 2024, with a strong emphasis on high-end raw material drug chains [4] - R&D investment in Hubei's pharmaceutical industry reached 5.4% of total industrial output, double the provincial average, with 114 new drug registrations, a 56.1% increase [5] Future Development Plans - Hubei aims to build a trillion-yuan health industry cluster in Wuhan, enhancing its competitiveness in high-end medical equipment and biopharmaceuticals [6] - The life and health industry in Wuhan is projected to reach 554.6 billion yuan in 2024, growing by 15.3% [7] - Hubei's strategic plans include fostering a national biopharmaceutical cluster and enhancing original innovation capabilities by 2027 [8]
湖北大健康产业迈上万亿级台阶 生物医药制造业年营收1235亿元
Chang Jiang Shang Bao·2025-06-08 23:09